Clinical Trials · NCT06162559
Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study
- Phase
- Phase 1
- Recruitment status
- Recruiting
- Sponsor
- The Netherlands Cancer Institute
- Enrollment
- 30
- Start date
- Dec 2023
- Locations
- 1 site, Netherlands
- Primary endpoint
- Incidence and severity of adverse events